



DMF 030298

**DMF ACKNOWLEDGEMENT**

WZ PACKAGING LTD  
ATTN: MARTIN JOHNSON  
HALESFIELD 18, TELFORD  
TF7 4JS, UNITED KINGDOM

Dear Martin Johnson,

The Food and Drug Administration acknowledges receipt of the following Drug Master File (DMF) submission:

**DMF NUMBER ASSIGNED:** 030298  
**DATE OF SUBMISSION:** FEBRUARY 15, 2016  
**DMF TYPE:** III  
**SUBJECT (TITLE):** 20 MICRON BLISTER FOIL  
**HOLDER:** WZ PACKAGING LTD  
**SUBMITTED BY:** WZ PACKAGING LTD  
**AGENT:** INTERTEK WILTON

All subsequent correspondence to this DMF should be identified with the information as provided above. One original and one copy should be submitted to the following address.

Food and Drug Administration  
Center for Drug Evaluation and Research  
Central Document Room  
Drug Master File Staff  
5901-B Ammendale Road  
Beltsville MD 20705-1266

Your DMF will be reviewed only in connection with a New Drug Application, Abbreviated New Drug Application, Investigational New Drug Application, Biological License Application, New Animal Drug Application, Abbreviated New Animal Drug Application, Investigational New Animal Drug Application, or DMF it is intended to support when a Letter of Authorization (LOA) is submitted to the DMF and a copy of the LOA is submitted in the application e.g., NDA, that references the DMF.

Currently, there is no requirement to submit or resubmit DMFs in any electronic format. However, beginning on May 5, 2017, new DMFs, as well as subsequent submissions to previously submitted DMFs (i.e., amendments) must be submitted electronically, in the format specified by FDA in the